活体供肾移植受者合并重型COVID-19疾病中肾动脉血栓形成的血管内治疗
本文报告一例女性活体供肾移植受者在近期感染COVID-19后出现移植肾肾动脉血栓形成,因存在肾衰竭或移植肾切除风险而采用导管定向溶栓治疗,残余血栓以覆膜支架隔绝,结果优良,无不良事件且肾功能改善。
要点
- 活体供肾移植受者感染SARS-CoV-2后移植肾肾动脉血栓形成风险可能呈指数级增加。
- 本例因肾衰竭或移植肾切除风险行导管定向溶栓,残余血栓以覆膜支架隔绝。
- 术后无不良事件,肾功能改善。
核心结论
- 本文报告了一例活体供肾移植受者合并重型COVID-19疾病中肾动脉血栓形成的血管内治疗。
研究设计与样本
- 病例报告:一例女性活体供肾移植受者,在近期COVID-19感染后出现移植肾肾动脉血栓形成。
主要发现
- 因存在肾衰竭或移植肾切除风险,行导管定向溶栓治疗。
- 残余血栓使用覆膜支架隔绝,结果优良。
- 无不良事件发生,肾功能改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Coronavirus disease 2019 (COVID-19) patients have a higher prevalence of micro-and macrovascular thrombotic events. However, the underlying mechanism for the increased thrombotic risk is not completely understood. Solid organ transplant recipients infected with SARS-CoV-2 may have an exponential increase in thrombotic risk and the best management strategy is unknown. CASE REPORT: A female kidney transplant recipient presented with allograft's renal artery thrombosis after a recent COVID-19 infection. Due to the risk of kidney failure or exclusion, catheter directed thrombolysis was performed. Residual thrombus was excluded using an endoprosthesis with an excellent result. There were no adverse events and kidney function improved. CONCLUSION: This paper reports the endovascular treatment of renal artery thrombosis in a living-donor kidney transplant recipient with severe COVID-19 disease.
引用
- Veterano C, Antunes I, Coelho A, et al. Endovascular Treatment of Renal Artery Thrombosis in Living-Donor Kidney Transplant Recipient With Severe COVID-19 Disease. J Endovasc Ther. 2022. PMID: 34994219. doi:10.1177/15266028211068756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。